UK Parliament Science and Technology Committee

UK Parliament Science and Technology Committee
Name	Science and Technology Committee
Jurisdiction	Parliament of the United Kingdom
Established	1987
Chamber	House of Commons
Parent body	House of Commons of the United Kingdom

UK Parliament Science and Technology Committee is a select committee of the House of Commons of the United Kingdom tasked with examining matters relating to science, technology, engineering and innovation across the United Kingdom of Great Britain and Northern Ireland, including oversight of public research bodies such as the UK Research and Innovation and regulators including the Medicines and Healthcare products Regulatory Agency, the Environment Agency (England), and the Food Standards Agency. It reports to the House of Commons of the United Kingdom and informs parliamentary scrutiny involving departments such as the Department for Business and Trade, the Department of Health and Social Care, and the Department for Environment, Food and Rural Affairs. The committee’s work intersects with institutions like the Wellcome Trust, the Royal Society, the Royal Academy of Engineering, and international bodies including the European Research Council, the Organisation for Economic Co-operation and Development, and the United Nations Educational, Scientific and Cultural Organization.

Overview and remit

The committee’s remit is defined by the House of Commons of the United Kingdom and focuses on scientific research, innovation policy, technological development, and the stewardship of public bodies such as UK Research and Innovation and the UK Space Agency. It conducts inquiries into issues linked to the National Health Service (England), the Met Office, the Civil Aviation Authority, and the Food Standards Agency, producing reports that advise ministers in the Department for Business and Trade and the Department of Health and Social Care. Its remit overlaps with scrutiny of legislation including the Science and Technology Act-era provisions, regulatory frameworks influenced by the European Union era agencies like the European Medicines Agency, and funding mechanisms involving the Research Excellence Framework and the Industrial Strategy.

History and composition

Formed as part of the proliferation of select committees in the late 20th century, the committee’s lineage traces through parliamentary reforms associated with figures such as Margaret Thatcher-era restructuring and later changes under Tony Blair and David Cameron. Membership comprises MPs nominated by party whips and appointed by the House of Commons of the United Kingdom, often including parliamentarians with links to constituencies and institutions like Cambridge University, Imperial College London, University of Oxford, University College London, and research centres such as CERN, Harwell Science and Innovation Campus, and the Francis Crick Institute. Chairs have included MPs prominent in science policy debates who liaise with stakeholders from the Royal Society, the Academy of Medical Sciences, and the British Science Association.

Responsibilities and procedures

Responsibilities include launching public inquiries, taking oral and written evidence from witnesses such as chief executives from UK Research and Innovation, chief scientific advisers from the Department for Environment, Food and Rural Affairs, and directors from bodies like the National Physical Laboratory, the Roslin Institute, and the Cell and Gene Therapy Catapult. Procedurally the committee follows the standing orders of the House of Commons of the United Kingdom, publishes reports, moves motions, and can summon witnesses from entities including the National Health Service (England), the Environment Agency (England), and private firms such as AstraZeneca, GlaxoSmithKline, and Rolls-Royce Holdings. It interacts with parliamentary peers from the House of Lords committees, engages with devolved administrations in Scotland, Wales, and Northern Ireland, and coordinates with international partners like the National Science Foundation (United States) and the German Research Foundation.

Major inquiries and reports

Notable inquiries have covered topics such as the response to pandemics involving the Public Health England transition to the UK Health Security Agency, vaccine development by AstraZeneca and collaborations with University of Oxford, the governance of artificial intelligence intersecting with work by DeepMind and the Alan Turing Institute, net zero and climate science engaging the Met Office and the Committee on Climate Change, and space policy involving the UK Space Agency and launch providers operating from sites like Spaceport Cornwall. Reports have examined research funding and the Research Excellence Framework, university-industry partnerships with firms like Rolls-Royce Holdings and BP, data governance in relation to the Information Commissioner's Office, and the implications of Brexit on the European Research Council and participation in Horizon programmes.

Impact on science policy and legislation

The committee’s findings have influenced ministerial decisions in the Department for Business and Trade, shaped amendments to bills considered in the House of Commons of the United Kingdom and the House of Lords, and affected funding allocations involving UK Research and Innovation and the British Business Bank. Its recommendations have informed policy instruments used by the National Institute for Health and Care Excellence, the Medicines and Healthcare products Regulatory Agency, and contributed to debates on statutory frameworks like revisions touching the Science and Technology Act provisions and regulatory approaches consistent with international agreements such as those negotiated with the European Union and referenced in G7 science communiqués. The committee’s work feeds into institutional decision-making at bodies such as the Royal Society and drives parliamentary scrutiny that influences research priorities at universities including University of Cambridge and University of Oxford.

Criticisms and controversies

Critics have argued the committee’s influence can be limited by parliamentary timetables, party politics tied to leaders such as Theresa May and Boris Johnson, and resource constraints affecting follow-up on recommendations; controversies have arisen when inquiries intersect with corporate interests like GlaxoSmithKline or national security considerations involving suppliers linked to Huawei and defence suppliers such as BAE Systems. Questions of independence have been raised in relation to appointments influenced by party whips in the House of Commons of the United Kingdom and in high-profile exchanges with chief executives from institutions like the Wellcome Trust and chief scientific advisers from the Department of Health and Social Care. Nonetheless, its reports remain cited by organisations including the Royal Academy of Engineering, the Academy of Medical Sciences, and international partners like the United Nations Educational, Scientific and Cultural Organization.

Category:Parliamentary committees of the United Kingdom